Department of Radiology, Michigan Medicine, 1500 E Medical Center Dr, Ann Arbor, MI 48109-5030.
Michigan Institute of Clinical and Health Research, University of Michigan, Ann Arbor, MI.
AJR Am J Roentgenol. 2019 Nov;213(5):W188-W193. doi: 10.2214/AJR.19.21424. Epub 2019 Jul 3.
The objective of our study was to explore whether clinical factors historically associated with contrast material-causative kidney injury (contrast-induced nephrotoxicity [CIN]) increase risk after use of IV iodinated low-osmolality contrast material (LOCM) in patients with stage IIIb-V chronic kidney disease. In this retrospective hypothesis-generating study, 1:1 propensity score matching was used to assess post-CT acute kidney injury (AKI) after unenhanced or contrast-enhanced CT in patients with stable estimated glomerular filtration rate (eGFR; 1112 patients with an eGFR = 30-44 mL/min/1.73 m and 86 patients with an eGFR < 30 mL/min/1.73 m and no dialysis). Historical risk factors including diabetes mellitus, age more than 60 years, hypertension, loop diuretic use, hydrochlorothiazide use, and cardiovascular disease were evaluated for modulation of CIN risk. Stepwise multivariable logistic regression was performed. Overall IV LOCM was an independent risk factor for post-CT AKI in patients with an eGFR of less than 30 mL/min/1.73 m (odds ratio, 3.96 [95% CI, 1.29-12.21]; = 0.016) but not in those with an eGFR of 30-44 mL/min/1.73 m ( = 0.24). In patients with an eGFR of less than 30 mL/min/1.73 m, the tested covariates did not significantly modify the risk of CIN ( = 0.096-0.832). In patients with an eGFR of 30-44 mL/min/1.73 m, risk of CIN emerged in those with cardiovascular disease ( = 0.015; number needed to harm from LOCM = 11 patients); the other tested cofactors had no significant effect ( = 0.108-0.822). CIN was observed when eGFR was less than 30 mL/min/1.73 m. In those with an eGFR of 30-44 mL/min/1.73 m, CIN was not observed with LOCM alone but was observed in the presence of cardiovascular disease. Other cofactors historically thought to increase CIN risk (e.g., diabetes mellitus) did not increase risk of CIN. Further study is needed to determine whether these exploratory results are true associations.
我们的研究目的是探讨在患有 IIIb-V 期慢性肾脏病的患者中,既往与造影剂导致肾损伤(对比剂诱导的肾病[CIN])相关的临床因素是否会增加使用静脉碘低渗对比剂(LOCM)后的风险。在这项回顾性假设生成研究中,使用 1:1 倾向评分匹配来评估稳定估算肾小球滤过率(eGFR;1112 例 eGFR=30-44 mL/min/1.73 m 和 86 例 eGFR<30 mL/min/1.73 m 且无透析)的患者进行增强 CT 前后的 CT 后急性肾损伤(AKI)。评估了包括糖尿病、年龄>60 岁、高血压、袢利尿剂使用、氢氯噻嗪使用和心血管疾病在内的既往危险因素是否能调节 CIN 风险。进行逐步多变量逻辑回归。对于 eGFR 小于 30 mL/min/1.73 m 的患者,总体静脉 LOCM 是 CT 后 AKI 的独立危险因素(优势比,3.96 [95%CI,1.29-12.21]; = 0.016),但对于 eGFR 为 30-44 mL/min/1.73 m 的患者则不是( = 0.24)。在 eGFR 小于 30 mL/min/1.73 m 的患者中,经测试的协变量并未显著改变 CIN 的风险( = 0.096-0.832)。在 eGFR 为 30-44 mL/min/1.73 m 的患者中,CIN 出现在患有心血管疾病的患者中( = 0.015;从 LOCM 获益的人数需要 = 11 名患者);其他经测试的混杂因素没有明显影响( = 0.108-0.822)。当 eGFR 小于 30 mL/min/1.73 m 时,会出现 CIN。在 eGFR 为 30-44 mL/min/1.73 m 的患者中,单独使用 LOCM 不会出现 CIN,但在存在心血管疾病时会出现 CIN。既往被认为会增加 CIN 风险的其他混杂因素(例如糖尿病)并未增加 CIN 的风险。需要进一步研究以确定这些探索性结果是否存在真实关联。